Arcutis Biotherapeutics (ARQT) to Release Quarterly Earnings on Wednesday

Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Arcutis Biotherapeutics to post earnings of $0.09 per share and revenue of $118.8530 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.07). The firm had revenue of $105.40 million for the quarter, compared to analysts’ expectations of $103.67 million. Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. On average, analysts expect Arcutis Biotherapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Arcutis Biotherapeutics Trading Up 2.1%

Arcutis Biotherapeutics stock opened at $28.42 on Wednesday. The stock has a market cap of $3.55 billion, a P/E ratio of -947.02 and a beta of 1.48. Arcutis Biotherapeutics has a fifty-two week low of $13.69 and a fifty-two week high of $31.77. The firm’s fifty day moving average price is $25.15 and its 200-day moving average price is $24.70. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.46 and a current ratio of 2.68.

Insider Activity

In related news, Director Howard G. Welgus sold 7,144 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $22.99, for a total transaction of $164,240.56. Following the transaction, the director directly owned 32,600 shares of the company’s stock, valued at approximately $749,474. This trade represents a 17.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Latha Vairavan sold 1,341 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $23.61, for a total value of $31,661.01. Following the completion of the sale, the chief financial officer owned 86,413 shares of the company’s stock, valued at $2,040,210.93. The trade was a 1.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 30,931 shares of company stock worth $730,086. 9.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ARQT. AQR Capital Management LLC boosted its stake in shares of Arcutis Biotherapeutics by 21.4% in the 1st quarter. AQR Capital Management LLC now owns 248,196 shares of the company’s stock valued at $3,882,000 after purchasing an additional 43,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Arcutis Biotherapeutics by 3.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after purchasing an additional 2,063 shares during the period. Creative Planning raised its position in Arcutis Biotherapeutics by 8.2% in the 2nd quarter. Creative Planning now owns 19,575 shares of the company’s stock worth $274,000 after purchasing an additional 1,477 shares during the period. JPMorgan Chase & Co. lifted its stake in Arcutis Biotherapeutics by 1.0% in the second quarter. JPMorgan Chase & Co. now owns 548,789 shares of the company’s stock worth $7,694,000 after purchasing an additional 5,407 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Arcutis Biotherapeutics by 4,562.5% in the second quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company’s stock worth $157,000 after purchasing an additional 10,950 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ARQT. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen raised Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.00.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.